Product Pipeline

Candidate & Indication Development Stage
R & D Preclinical Phase 1 Phase 2 Phase 3
Iomab-B CD451 BMT (Bone Marrow Transplant)
Patients over age 55 with relapsed or refractory AML
Induction and conditioning agent prior to a BMT
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Actimab-A (f.d.) CD33 AML
Newly diagnosed patients
with AML over age 60
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Bismab-A CD332 AML Development Discontinued
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Actimab-A (s.d.) CD33 AML Development Discontinued
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-M CD33 Multiple Myeloma
Relapsed or refractory patients age 18 and above
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Fourth Program
Undisclosed
R & D Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-C Colon Cancer
R & D Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-P Prostate Cancer
R & D Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-Br Brain Cancer
R & D Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
  1. BMT or HSCT (Hematopoietic Stem Cell Transplantation) is a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient.
  2. ATNM has decided to discontinue development of Bismab-A at this time due to supply, logistics and cost reasons. Actimab-A is the second generation drug of Bismab-A